Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An optic atrophy caused by a variation in the RTN4IP1; the optic atrophy can be associated with neurological involvement, including intellectual disability, ataxia, seizures.
Features include always present findings: Color vision defect, Reduced visual acuity, and Optic disc pallor; and very common findings: Photophobia. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 5 | Blind-spot enlargement, Color vision defect, Nystagmus |
RTN4IP1 function has not been fully characterized.
Optic atrophy 10 with or without ataxia, intellectual disability, and seizures is associated with mutations in the RTN4IP1 gene on chromosome 6.
Genetic testing for RTN4IP1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for optic atrophy 10 with or without ataxia, intellectual disability, and seizures has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 1 very common feature, 4 common features.
No clinical trials have been registered for optic atrophy 10 with or without ataxia, intellectual disability, and seizures.
400 publications have been identified in PubMed for optic atrophy 10 with or without ataxia, intellectual disability, and seizures. Kisho has analyzed 33 by research type. Research spans Basic Science / Preclinical (39%), Case Report / Case Series (18%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 13 |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 6:12 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
3 |
Mild intellectual disability, Ataxia, Myoclonic seizure |
Age of onset: infancy.
Patient case studies | 6 | 18% |
Research summaries | 5 | 15% |
Disease patterns and progression | 4 | 12% |
Clinical study results | 2 | 6% |
Other research | 1 | 3% |
Testing and diagnosis research | 1 | 3% |
New treatment approaches | 1 | 3% |
Mars JA (2026). [PMID: 36256781](https://pubmed.ncbi.nlm.nih.gov/36256781/). *Unknown Journal*. [Review / Meta-Analysis]
Digitale Selvaggio L (2026). [PMID: 41609474](https://pubmed.ncbi.nlm.nih.gov/41609474/). *Endocr Connect*. [Case Report / Case Series]
Shah M (2026). [PMID: 29083768](https://pubmed.ncbi.nlm.nih.gov/29083768/). *Unknown Journal*. [Review / Meta-Analysis]
Abou-Samra A (2025). [PMID: 40919301](https://pubmed.ncbi.nlm.nih.gov/40919301/). *J Vitreoretin Dis*. [Epidemiology / Natural History]
Nakirikanti AS (2025). [PMID: 40023555](https://pubmed.ncbi.nlm.nih.gov/40023555/). *J Neuroimmunol*. [Epidemiology / Natural History]
Tachibana M (2025). [PMID: 40751186](https://pubmed.ncbi.nlm.nih.gov/40751186/). *BMC Ophthalmol*. [Case Report / Case Series]
Ai C (2025). [PMID: 40036074](https://pubmed.ncbi.nlm.nih.gov/40036074/). *JCI Insight*. [Gene Therapy / Novel Therapeutics]
Jesuthasan A (2025). [PMID: 40649801](https://pubmed.ncbi.nlm.nih.gov/40649801/). *Int J Mol Sci*. [Review / Meta-Analysis]
Unknown (2025). [PMID: 40773218](https://pubmed.ncbi.nlm.nih.gov/40773218/). *J Neuroophthalmol*. [Other]
Pellattiero A (2025). [PMID: 40614185](https://pubmed.ncbi.nlm.nih.gov/40614185/). *Sci Adv*. [Basic Science / Preclinical]